CMES8 Updates in Cardiovascular Risk Reduction in Type 2 Diabetes: New Insights and Outcomes in Treatment Options

Program: CMES Ancillary Events
Clinical Session
Sunday, April 3, 2016: 6:30 PM-9:30 PM
Grand Ballroom (The Westin)
Supported by an educational grant from Boehringer Ingelheim and Lilly USA, LLC

Registration is required for this session:

Learning Objectives:

Upon completing this activity, learners will be better able to:

  • Summarize the most recent guideline recommendations for screening for coronary artery disease in T2D including specific goals in reducing risk factors and appropriate biochemical targets
  • Evaluate the benefits of statin therapy in patients to reduce CV risk taking into consideration recently described associations with new onset T2D
  • Describe the cardiovascular safety of new medications for glycemic control
  • Describe the mechanism of action of SGLT-2 inhibitors on kidney, liver, and vascular systems
  • Understand the efficacy and safety results of the EMPA-REG Outcome trial and the questions it raises about the potential benefits and risks of empagliflozin and other SGLT-2 inhibitors in people with T2DM, with or without CVD
7:00 PM

Bernard Zinman, Mail Box 17, University of Toronto, Toronto, ON, Canada
Disclosure Not Provided: BZ
7:05 PM

Naveed Sattar, PhD, FRCP, FRCPath, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom
Disclosure Not Provided: NS
7:30 PM

Hertzel C Gerstein, MD, MSc, FRCPC, Director, Division of Endocrinology & Metabolism, McMaster University, Hamilton, ON, Canada
Disclosures:
HCG: Advisory Group Member, Abbott Laboratories, Advisory Group Member, Amgen, Speaker, Astra Zeneca, Principal Investigator, Astra Zeneca, Advisory Group Member, Eli Lilly & Company, Principal Investigator, Eli Lilly & Company, Principal Investigator, Merck & Co., Advisory Group Member, Merck & Co., Advisory Group Member, Novo Nordisk, Recipient Award, Sanofi, Consultant, Sanofi.
7:50 PM

Silvio E Inzucchi, MD, Section of Endocrinology, Yale School of Medicine, New Haven, CT
Disclosures:
SEI: Consultant, Astra Zeneca, Committee Member, Novo Nordisk, Advisory Group Member, Jansen Pharmaceuticals, Advisory Group Member, Merck & Co., Coinvestigator, Takeda, Consultant, Sanofi, Committee Member, Daiichi Sankyo.
8:10 PM

Bernard Zinman, Mail Box 17, University of Toronto, Toronto, ON, Canada
Disclosures:
BZ: Chairman, Boehringrer Ingelheim, Chairman, Astra Zeneca, Chairman, Merck & Co., Chairman, Sanofi, Chairman, Novo Nordisk.
See more of: CMES Ancillary Events